Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

538
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
538
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

810
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
810
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

602
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
602
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

864
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
864
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.6K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Electrophysiology of Disease Remission in Chronic Inflammatory Demyelinating Polyneuropathy.

European journal of neurology·2026
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

NPJ digital medicine·2026
Same author

Authors response: other autoimmune disorders in chronic immune-mediated neuropathies: why trying to find out does matter.

Expert review of clinical immunology·2026
Same author

Raw, centile and individualised minimal clinically important differences for the MMN-Rasch-built Overall Disability Scale<sup>©</sup> in the monitoring of multifocal motor neuropathy.

Journal of neurology·2026
Same author

Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management.

ImmunoTargets and therapy·2026

Related Experiment Video

Updated: Feb 17, 2026

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.8K

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Richard Ac Hughes1, Man Mohan Mehndiratta, Yusuf A Rajabally

  • 1MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, PO Box 114, Queen Square, London, UK, WC1N 3BG.

The Cochrane Database of Systematic Reviews
|November 30, 2017
PubMed
Summary

Corticosteroids show limited evidence for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). While observational studies suggest benefits, randomized trials have low-quality evidence, and long-term use carries risks. Further research is needed to predict treatment response.

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.2K
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.4K

Related Experiment Videos

Last Updated: Feb 17, 2026

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.8K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.2K
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.4K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disabling autoimmune disorder.', 'Corticosteroids are a common treatment, but evidence from randomized trials is limited.', 'This review sought to update evidence on corticosteroid efficacy and safety for CIDP.'], 3.

Purpose of the Study:

  • To evaluate corticosteroid treatment for CIDP versus placebo or no treatment.', 'To compare different corticosteroid regimens for CIDP management.'], 2.

Main Methods:

  • Searched major databases (Cochrane, MEDLINE, Embase) and clinical trials registries for randomized controlled trials (RCTs) up to November 2016.', 'Included RCTs or quasi-RCTs diagnosing CIDP using internationally accepted criteria.', 'Assessed risk of bias and strength of evidence using GRADE; primary outcome was disability change.'], 3.

Main Results:

  • One low-quality RCT on prednisone showed uncertain benefits for CIDP, with one death reported.', 'A moderate-quality RCT found little difference between daily prednisolone and monthly high-dose dexamethasone in remission or disability.', 'Side effects were similar, though moon facies and sleeplessness were less common with dexamethasone.'], 3.

Conclusions:

  • Evidence for oral prednisone in CIDP is very low quality, despite its common use.', 'High-dose monthly dexamethasone appears similar in efficacy to daily prednisolone, with potentially fewer specific side effects.', 'Further research is required to identify predictors of corticosteroid response in CIDP.'] 3.